Benign Prostatic Hyperplasia (BPH)

Also known as: Benign Prostatic Hyperplasia / Prostatauxe

DrugDrug NameDrug Description
DB00346AlfuzosinAlfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.
DB01126DutasterideDutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner.[A1909] Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediator that plays a role in the development and enlargement of the prostate gland. Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to enhance the therapeutic response. Its clinical efficacy against benign prostate hyperplasia in male patients is comparable to that of [finasteride], a specific type II 5α-reductase inhibitor. However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled trials in androgenetic alopecia.[A178333,A178336]
DB01216FinasterideFinasteride is a synthetic 4-azasteroid compound[Label] and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or the need for surgical procedures.[Label,L6244] In 1998, it was approved by the FDA to treat male pattern hair loss.[L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker. Both benign prostatic hyperplasia and androgenic alopecia are androgen-dependent disorders that are characterized by _in situ_ high levels of DHT.[A178159] In the treatment of benign prostate hyperplasia, alpha-blockers such as [tamsulosin] and [terazosin] are also used. Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in benign prostate hyperplasia and androgenic alopecia, thus reducing the risk for secondary complications while providing symptom control.[A2132]
DB00457PrazosinPrazosin, also known as _Minipress_, is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988 [L5828]. It belongs to the class of drugs known as alpha-1 antagonists [FDA label], [A176630]. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares [A176618, A176621, A176624].
DB06207SilodosinSilodosin is an α1-adrenoceptor antagonist that is selective for the prostate. Silodosin is for symptomatic treatment of benign prostatic hyperplasia. FDA approved Oct 9, 2008.
DB00820TadalafilTadalafil is an orally administered drug used to treat male erectile dysfunction (impotence). It is marketed worldwide under the brand name Cialis. It is a phosphodiesterase 5 (PDE5) inhibitor. Tadalafil's distinguishing pharmacologic feature is its longer half-life (17.5 hours) compared with Viagra and Levitra (4-5 hours). This longer half-life results in a longer duration of action and is, in part, responsible for the Cialis nickname of the "weekend pill." This longer half-life also is the basis of current investigation for tadalafil's use in pulmonary arterial hypertension as a once-daily therapy.
DB00706TamsulosinTamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]
DB01162TerazosinTerazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].
DrugDrug NameTargetType
DB00346AlfuzosinAlpha-1A adrenergic receptortarget
DB00346AlfuzosinAlpha-1B adrenergic receptortarget
DB00346AlfuzosinAlpha-1D adrenergic receptortarget
DB00346AlfuzosinCytochrome P450 3A4enzyme
DB00346AlfuzosinPotassium voltage-gated channel subfamily H member 2target
DB01126Dutasteride3-oxo-5-alpha-steroid 4-dehydrogenase 1target
DB01126Dutasteride3-oxo-5-alpha-steroid 4-dehydrogenase 2target
DB01126DutasterideCytochrome P450 3A4enzyme
DB01126DutasterideSodium-dependent dopamine transportertransporter
DB01126DutasterideSynaptic vesicular amine transportertransporter
DB01126DutasterideSerum albumincarrier
DB01126DutasterideAlpha-1-acid glycoprotein 1carrier
DB01126DutasterideCytochrome P450 3A5enzyme
DB01216Finasteride3-oxo-5-alpha-steroid 4-dehydrogenase 1target
DB01216FinasterideCytochrome P450 3A4enzyme
DB01216Finasteride3-oxo-5-alpha-steroid 4-dehydrogenase 2target
DB01216Finasteride3-oxo-5-beta-steroid 4-dehydrogenasetarget
DB01216FinasterideCytochrome P450 3A5enzyme
DB01216FinasterideCytochrome P450 3A7enzyme
DB01216FinasterideSolute carrier family 12 member 5transporter
DB00457PrazosinAlpha-1A adrenergic receptortarget
DB00457PrazosinAlpha-1B adrenergic receptortarget
DB00457PrazosinAlpha-1D adrenergic receptortarget
DB00457PrazosinPotassium voltage-gated channel subfamily H member 2target
DB00457PrazosinAlpha-1-acid glycoprotein 1carrier
DB00457PrazosinSolute carrier family 22 member 1transporter
DB00457PrazosinSolute carrier family 22 member 3transporter
DB00457PrazosinMultidrug resistance protein 1transporter
DB00457PrazosinATP-binding cassette sub-family G member 2transporter
DB00457PrazosinAlpha-2A adrenergic receptortarget
DB00457PrazosinAlpha-2B adrenergic receptortarget
DB00457PrazosinAlpha-1 adrenergic receptorstarget
DB06207SilodosinAlpha-1D adrenergic receptortarget
DB06207SilodosinCytochrome P450 3A4enzyme
DB06207SilodosinMultidrug resistance protein 1transporter
DB06207SilodosinMultidrug resistance protein 3transporter
DB06207SilodosinAlpha-1A adrenergic receptortarget
DB06207SilodosinAlpha-1B adrenergic receptortarget
DB06207SilodosinUDP-glucuronosyltransferase 2B7enzyme
DB00820TadalafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00820TadalafilCytochrome P450 3A4enzyme
DB00820TadalafilDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11Atarget
DB00820TadalafilCytochrome P450 3A5enzyme
DB00706TamsulosinAlpha-1A adrenergic receptortarget
DB00706TamsulosinAlpha-1D adrenergic receptortarget
DB00706TamsulosinAlpha-1B adrenergic receptortarget
DB00706TamsulosinAlpha-1-acid glycoprotein 1carrier
DB00706TamsulosinCytochrome P450 2D6enzyme
DB00706TamsulosinCytochrome P450 3A4enzyme
DB01162TerazosinAlpha-1A adrenergic receptortarget
DB01162TerazosinAlpha-1B adrenergic receptortarget
DB01162TerazosinAlpha-1D adrenergic receptortarget
DB01162TerazosinPotassium voltage-gated channel subfamily H member 2target
DB01162TerazosinPotassium voltage-gated channel subfamily H member 6target
DB01162TerazosinPotassium voltage-gated channel subfamily H member 7target
DB01162TerazosinMultidrug resistance protein 1transporter
DB01162TerazosinTransforming growth factor beta-1target
DrugDrug NamePhaseStatusCount
DB00083Botulinum toxin type A0Withdrawn1
DB01126Dutasteride1Completed3
DB01126Dutasteride1Unknown Status1
DB01216Finasteride1Completed1
DB05918LS111Completed1
DB14317Pomegranate1Unknown Status1
DB01591Solifenacin1Completed2
DB00820Tadalafil1Completed5
DB00820Tadalafil1Unknown Status1
DB11812Talaporfin1Completed1
DB00706Tamsulosin1Completed5
DB00083Botulinum toxin type A1 / 2Completed1
DB00898Ethanol1 / 2Completed1
DB09153Sodium chloride1 / 2Completed1
DB05160Topsalysin1 / 2Completed1
DB00346Alfuzosin2Completed1
DB00083Botulinum toxin type A2Completed3
DB00083Botulinum toxin type A2Recruiting1
DB00482Celecoxib2Completed1
DB00590Doxazosin2Completed1
DB11674Equol2Completed1
DB12801Erteberel2Terminated1
DB00294Etonogestrel2Terminated1
DB01216Finasteride2Completed1
DB05918LS112Completed2
DB06266Lonidamine2Terminated1
DB05493NX-12072Completed1
DB12581Ozarelix2Terminated1
DB01229Paclitaxel2Active Not Recruiting1
DB00203Sildenafil2Completed1
DB06207Silodosin2Completed1
DB09153Sodium chloride2Completed1
DB00820Tadalafil2Completed3
DB11812Talaporfin2Completed2
DB00706Tamsulosin2Completed2
DB00706Tamsulosin2Recruiting1
DB04937Tertomotide2Completed1
DB12747Tertomotide2Completed1
DB05160Topsalysin2Completed1
DB06267Udenafil2Withdrawn1
DB00862Vardenafil2Completed1
DB00083Botulinum toxin type A2 / 3Completed1
DB00820Tadalafil2 / 3Completed1
DB00346Alfuzosin3Completed1
DB00346Alfuzosin3Terminated1
DB01126Dutasteride3Completed1
DB01126Dutasteride3Terminated2
DB01216Finasteride3Completed1
DB01216Finasteride3Terminated2
DB01216Finasteride3Withdrawn1
DB06266Lonidamine3Terminated1
DB05493NX-12073Completed4
DB14360Saw palmetto3Completed1
DB06207Silodosin3Completed4
DB01591Solifenacin3Recruiting2
DB00820Tadalafil3Completed10
DB00820Tadalafil3Recruiting1
DB00706Tamsulosin3Completed8
DB00706Tamsulosin3Recruiting3
DB00706Tamsulosin3Terminated2
DB05160Topsalysin3Completed1
DB00346Alfuzosin4Completed2
DB00346Alfuzosin4Withdrawn1
DB00482Celecoxib4Withdrawn1
DB00537Ciprofloxacin4Completed1
DB00586Diclofenac4Recruiting1
DB00590Doxazosin4Withdrawn1
DB01126Dutasteride4Completed5
DB01126Dutasteride4Terminated1
DB01126Dutasteride4Unknown Status1
DB01216Finasteride4Active Not Recruiting1
DB01216Finasteride4Unknown Status1
DB00588Fluticasone propionate4Unknown Status1
DB01002Levobupivacaine4Completed1
DB00281Lidocaine4Completed1
DB08893Mirabegron4Completed1
DB08893Mirabegron4Not Yet Recruiting1
DB06207Silodosin4Completed3
DB01591Solifenacin4Completed3
DB00820Tadalafil4Completed1
DB00706Tamsulosin4Active Not Recruiting1
DB00706Tamsulosin4Completed5
DB00706Tamsulosin4Not Yet Recruiting1
DB00706Tamsulosin4Withdrawn1
DB01162Terazosin4Withdrawn1
DB00624Testosterone4Completed1
DB01036Tolterodine4Completed1
DB01036Tolterodine4Unknown Status1
DB00346AlfuzosinNot AvailableCompleted1
DB00633DexmedetomidineNot AvailableCompleted1
DB00590DoxazosinNot AvailableCompleted1
DB01126DutasterideNot AvailableCompleted3
DB01126DutasterideNot AvailableUnknown Status1
DB00706TamsulosinNot AvailableUnknown Status2